Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 Patients | Zendy

Casper Rokx | Zendy; Marc van der Valk | Zendy; Annelies Verbon | Zendy; Bart Rijnders | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 Patients

Author(s) -

Casper Rokx,

Marc van der Valk,

Annelies Verbon,

Bart Rijnders

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit517

Subject(s) - medicine , sarcoma , refractory (planetary science) , observational study , peginterferon alfa 2a , cohort , cohort study , kaposi's sarcoma , oncology , gastroenterology , immunology , virus , pathology , ribavirin , human herpesvirus , hepatitis c virus , physics , astrobiology

In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research